Anupam Rasayan pledges subsidiary stakes to secure ₹300 crore debt
- Anupam Rasayan approves pledge of 100% stake in Mates Visa Consultancy to secure ₹300 crore NCD issuance
- Parent company provides unconditional corporate guarantee for the subsidiary's debt obligations
- Call option granted to Purebliss Pharma to purchase all MVCPL securities held by Anupam Rasayan
- Separate pledge created over 15% stake in Purebliss Pharma to support its financing facilities

*this image is generated using AI for illustrative purposes only.
Anupam Rasayan India Ltd has approved the pledge of its entire stake in a wholly owned subsidiary and a partial stake in another associate to facilitate financing. The Board of Directors sanctioned these security documents on September 17, 2026, enabling debt issuance by its subsidiaries.
The primary transaction involves Mates Visa Consultancy Private Limited (MVCPL), a wholly owned subsidiary. MVCPL plans to issue up to ₹300 crore worth of senior secured unrated unlisted redeemable non-convertible debentures via private placement. Each debenture carries a face value of ₹1,00,000, with a maximum issuance of 30,000 units.
Security Structure
To secure these instruments, Anupam Rasayan will execute specific transaction documents:
- A deed of pledge creating a first-ranking charge over 100% of the equity shares of MVCPL held by the parent company.
- An unconditional corporate guarantee covering all amounts payable under the Mates Debenture Trust Deed.
- A call option agreement granting Purebliss Pharma Solutions Private Limited the right to purchase all securities of MVCPL held by Anupam Rasayan on a fully diluted basis.
Additionally, the board approved a separate pledge over the company’s 15% stake in Purebliss Pharma Solutions Private Limited. This move supports financing facilities being availed by Purebliss. The pledge creates a first-ranking exclusive charge over these equity shares.
Execution Status
The finalisation and execution of these documents remain pending. The company will issue further disclosures to stock exchanges upon signing, as required under Regulation 30 of the SEBI Listing Regulations and Annexure 18 of the SEBI circular dated January 30, 2026. The board meeting commenced at 6:37 pm and concluded at 7:01 pm.
Historical Stock Returns for Anupam Rasayan
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +0.25% | -3.93% | -6.81% | -6.81% | -6.81% | -6.81% |
How will the ₹300 crore debt issuance impact Anupam Rasayan's overall leverage ratios and credit rating outlook?
What strategic rationale drives the pledge of 100% equity in MVCPL, and does this signal potential divestment or restructuring plans?
How might the call option granted to Purebliss Pharma Solutions influence future corporate governance or control dynamics within the group?

































